Brexafemme (ibrexafungerp) — Highmark
vulvovaginal candidiasis (VVC)
Preferred products
- fluconazole
Initial criteria
- Diagnosis of VVC (ICD10: B37.3) supported by ONE of the following: microscopic confirmation of budding yeasts or hyphae OR a positive culture for Candida
- Member has experienced fewer than 3 episodes of VVC in the last year
- Member meets ONE of the following: therapeutic failure, contraindication, or intolerance to fluconazole tablet OR positive culture for a non-albicans Candida with therapeutic failure, contraindication, or intolerance to a non-fluconazole oral or topical azole regimen
Approval duration
1 month